Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice

Xenobiotica

Volumn 40, Issue 4, 2010, Pages 282-290

  Kudo, T ^a   Toda, T ^a   Ushiki, T ^a   Ohi, K ^a   Ikarashi, N ^a   Ochiai, W ^a   Sugiyama, K ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Cytochrome P450 (Cyp) 3a; Insulin; Mice; Small intestine; Streptozotocin; Tsumura, Suzuki, obese, diabetes (TSOD)

Indexed keywords

CYTOCHROME P450 3A; INSULIN; SODIUM CHLORIDE; STREPTOZOCIN; TRIAZOLAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME SUBSTRATE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SMALL INTESTINE; SPECIES COMPARISON; STREPTOZOCIN DIABETES;

ANIMALS; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INTESTINE, SMALL; KINETICS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, OBESE; MICROSOMES; MICROSOMES, LIVER; TRIAZOLAM;

MUS;

EID: 77949427736     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003596809     Document Type: Article

References (29)

1. Adithan C, Danda D, Shashindran CH, Bapna JS, Swaminathan RP, Chandrasekar S. (1989). Differential effect of type I and type II diabetes mellitus on antipyrine elimination. Meth Find Exp Clin Pharmacol 11:755-758
2. Dong B, Qatanani M, Moore DD. (2009). CAR mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology 50:662-669
3. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. (1995). Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 58:127-131
4. Iizuka S, Suzuki W, Tabuchi M, Nagata M, Imamura S, Kobayashi Y, Kanitani M, Yanagisawa T, Kase Y, Takeda S, Aburada M, Takahashi KW. (2005). Diabetic complications in a new animal model (TSOD mouse) of spontaneous NIDDM with obesity. Exp Anim 54:71-83.
5. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, Hering U, Bulitta J, Schreiner P, Sörgel F, Fuhr U. (2002). Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 71:21-29
6. Kharasch ED, Walker A, Hoffer C, Sheffels P. (2004). Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466
7. Kudo T, Shimada T, Toda T, Igeta S, Suzuki W, Ikarashi N, Ochiai W, Ito K, Aburada M, Sugiyama K. (2009). Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Xenobiotica 39:889-902.
8. Laemmli UK. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
9. Levert KL, Waldrop GL, Stephens JM. 2002. A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis. J Biol Chem 277:16347-16350
10. Lilja JJ, Kivistö KT, Neuvonen PJ. (1998). Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477-483
11. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol regent. J Biol Chem 193:265-275
13. Marques MP, Coelho EB, Dos Santos NA, Geleilete TJ, Lanchote VL. (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58:607-614
14. Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. (2000). Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182-190
15. Miura T, Suzuki W, Ishihara E, Arai I, Ishida H, Seino Y, Tanigawa K. (2001). Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur J Endocrinol 145:785-790
16. Mizutani S, Gomi H, Hirayama I, Izumi T. (2006). Chromosome 2 locus Nidd5 has a potent effect on adiposity in the TSOD mouse. Mamm Genome 17:375-384
17. Nakashima K, Yamamoto K, Al-Dirbashi OY, Nakashima MN. (2002). Expression profile of liver genes in response to hepatotoxicants identified using a SAGE - based customized DNA microarray system. Biomed Chromatogr 16:219-223
18. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628
19. Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson MF, Stepanavage M, Vega JM. (1999). Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 66:358-366
20. Sakuma T, Honma R, Maguchi S, Tamaki H, Nemoto N. (2001). Different expression of hepatic and renal cytochrome P450s between the streptozotocin-induced diabetic mouse and rat. Xenobiotica 31:223-237
21. Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. (2002). Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90:115-160
22. Suzuki W, Iizuka S, Tabuchi M, Funo S, Yanagisawa T, Kimura M, Sato T, Endo T, Kawamura H. (1999). A new mouse model of spontaneous diabetes derived from ddY strain. Exp Anim 48:181-189
23. Takahashi A, Tabuchi M, Suzuki W, Iizuka S, Nagata M, Ikeya Y, Takeda S, Shimada T, Aburada M. (2006). Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes mellitus and obesity. Metabolism 55:1664-1669
24. van Herwaarden AE, Wagenaar E, van Der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van Der Valk MA, van Tellingen O, van Der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592
25. Woodcroft KJ, Novak RF. (1997). Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem Biol Interact 107:75-91.
26. Woodcroft KJ, Novak RF. (1999). Insulin differentially affects xenobiotic-enhanced, cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther 289:1121-1127
27. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885
28. Zysset T, Wietholtz H. (1988). Differential effect of type I and type II diabetes on antipyrine disposition in man. Eur J Clin Pharmacol 34:369-375
29. Zysset T, Wietholtz H. (1991). Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus. Eur J Clin Pharmacol 41:449-452